MAIA Biotechnology, Inc. disclosed the presentation of a clinical trial poster at the European Lung Cancer Congress 2026 on March 27, 2026, which was also posted to the company's website and filed as an exhibit. The poster contains forward-looking statements regarding the THIO-101 trial.
Key takeaways
A poster titled 'Sustained Response and Long-Term Therapeutic Benefits Beyond Treatment Cessation in Abstract NSCLC Relapsed-Patients Treated with Ateganosine and ICI in the THIO-101 Trial' was prepared.
The poster was presented at the European Lung Cancer Congress 2026 (ELCC) in Copenhagen, Denmark, on March 27, 2026.
The poster was posted to the Company's website on March 27, 2026.
A copy of the poster is filed as Exhibit 99.1 to this Current Report on Form 8-K.